Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00370916 · ClinicalTrials.gov registry record · NA
Reducing Transition Drug Risk
A NA study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- NA
- Development phase
- 612
- Enrollment target
NCT00370916: Completed NA study, sponsored by US Department of Veterans Affairs.
NCT00370916 is a NA study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 612 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00370916, a NA study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- NA
- Development phase
- 612 participants
- Enrollment target
Study Summary
Patient transfer between sites of care is regular practice during an episode of care in our current health care system. Yet inter-site transfer is associated with lapses in care quality that adversely affect patient outcomes. A common iatrogenic harm precipitated at the time of transfer is harm from drug prescribing, or adverse drug events (ADEs). In this study we will evaluate a medication reconciliation tool developed to help providers make effective prescribing decisions at the time of transfer between VA sites of care (Improved Prescribing after Transfer (IPT)). We will evaluate the quantitative effectiveness of the tool in reducing transition drug risk and ADEs. We additionally will conduct focus group discussions and cognitive task analysis among end-users to better understand how providers make drug-prescribing decisions at the time of transfer and to assess factors influencing effective use of the tool.
Interventions
- BEHAVIORAL Physician-initiated medication reconciliation
- BEHAVIORAL Pharmacist-initiated medication reconciliation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 612 participants |
| Start Date | 2005-10 |
| Est. Completion | 2010-09 |
| Phase | NA |
What the finished NCT00370916 record still lists
NCT00370916 is an interventional study that assigns participants to a tested intervention. The registered 612 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 2 interventions - of which Physician-initiated medication reconciliation is the first listed.
NCT00370916 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00370916 about?
NCT00370916 is a clinical study titled "Reducing Transition Drug Risk". Patient transfer between sites of care is regular practice during an episode of care in our current health care system. Yet inter-site transfer is associated with lapses in care quality that adversely affect patient outcomes. A common iatrogenic harm precipitated at the time of transfer is harm from...
What is the current status of trial NCT00370916?
This trial is currently completed. It is a NA study. The enrollment target is 612 participants. The study started on 2005-10. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00370916?
The interventions under investigation include: Physician-initiated medication reconciliation (BEHAVIORAL), Pharmacist-initiated medication reconciliation (BEHAVIORAL).
Who is sponsoring clinical trial NCT00370916?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00370916's enrollment target sits among peer trials
612 161st of 2000 higher than 1,840 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04224493 · 612 participants · Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
- NCT04590326 · 612 participants · Phase 1
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- NCT06266416 · 612 participants · NA
IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)
- NCT01810913 · 613 participants · Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia